Solute carrier family 22 member 18 (SLC22A18)

Solute carrier family 22 member 18 (SLC22A18) is an imprinted tumor-suppressor gene and a transmembrane transporter protein primarily involved in organic cation transport, likely using a proton antiport mechanism. It plays an important role in xenobiotic and drug excretion in the kidney, lipid metabolism regulation, and has preferential maternal allele expression. Mutations and loss of function are associated with a variety of cancers (lung, breast, Wilms tumor, rhabdomyosarcoma, adrenocortical carcinoma) and congenital syndromes such as Beckwith-Wiedemann syndrome. SLC22A18 mediates transmembrane export of drugs (including chloroquine and quinidine derivatives), and dysfunction may contribute to drug pharmacokinetics and cancer risk.

Other names

Solute carrier family 67 member 1SLC67A1BWR1ATSSC5ITMSLC22A18SLC22A1LBWSCR1AORCTL2IMPT1Tumor-Suppressing Subchromosomal Transferable Fragment Candidate Gene 5 ProteinImprinted Multi-Membrane-Spanning Polyspecific Transporter-Related Protein 1Beckwith-Wiedemann Syndrome Chromosomal Region 1 Candidate Gene A ProteinImprinted Multi-Membrane-Spanning Polyspecific Transporter-Like Gene 1Organic Cation Transporter-Like Protein 2Tumor-Suppressing STF CDNA 5 ProteinSolute Carrier Family 67 Member A1Efflux Transporter-Like ProteinP45-BWR1AHETSolute Carrier Family 22 Member 1-LikeOrganic Cation Transporter Like 2ORCTL-2

Transport inhibition or modulation (drugs may interfere with transporter function, affecting organic cation and drug excretion, e.g., by blocking efflux, substrate competition, or altering the proton antiport mechanism)